Recent clinical trials of hypertension management

Hypertension

Volumn 62, Issue 1, 2013, Pages 3-7

  Jennings, Garry L R ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALISKIREN; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ATENOLOL; BENDROFLUMETHIAZIDE; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; FOSINOPRIL; HYDROCHLOROTHIAZIDE; NEUROPEPTIDE Y; PERINDOPRIL; PLACEBO; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN;

ADRENERGIC SYSTEM; ALGORITHM; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CAROTID SINUS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DIET THERAPY; DNA POLYMORPHISM; DRUG EFFICACY; DRUG INDUSTRY; ELECTRONIC MEDICAL RECORD; ELECTROSTIMULATION; FOLLOW UP; FRAMINGHAM RISK SCORE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; KIDNEY DENERVATION; KIDNEY INNERVATION; KIDNEY TRANSPLANTATION; NERVOUS SYSTEM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRESSORECEPTOR; PRIORITY JOURNAL; PULSE PRESSURE; QUALITY OF LIFE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE TRAINING; RESISTANT HYPERTENSION; SENSORY NERVE; SODIUM RESTRICTION; SYMPATHECTOMY; VASCULAR RESISTANCE; WEIGHT REDUCTION;

ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERTENSION; TREATMENT OUTCOME;

EID: 84880760943     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.00863     Document Type: Article

References (42)

1. Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension. 2011;58:1008-1013.
2. Bakris GL, Lindholm LH, Black HR, Krum H, Linas S, Linseman JV, Arterburn S, Sager P, Weber M. Divergent results using clinic and ambulatory blood pressures: report of a darusentan-resistant hypertension trial. Hypertension. 2010;56:824-830.
3. Smithwick RH, Thompson JE. Splanchnicectomy for essential hypertension; results in 1,266 cases. J Am Med Assoc. 1953;152:1501-1504.
4. Esler M, Ferrier C, Lambert G, Eisenhofer G, Cox H, Jennings G. Biochemical evidence of sympathetic hyperactivity in human hypertension. Hypertension. 1991;17(4 Suppl):III29-III35.
5. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Symplicity HTN-2 investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension: a randomized controlled trial. Lancet 2010;376:1903-1909.
6. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto- control hypertensive patients: prospective case series. Hypertension. 2012;60:1485-1490.
7. Mahfoud F, Cremers B, Janker J, et al. Renal hemodynamics and renal function after catheter-based renal sympathetic denervation in patients with resistant hypertension. Hypertension. 2012;60:419-424.
8. Lambert GW, Hering D, Esler MD, Marusic P, Lambert EA, Tanamas SK, Shaw J, Krum H, Dixon JB, Barton DA, Schlaich MP. Health-related quality of life after renal denervation in patients with treatment-resistant hypertension. Hypertension. 2012;60:1479-1484.
9. Daugherty SL, Powers JD, Magid DJ, Masoudi FA, Margolis KL, O'Connor PJ, Schmittdiel JA, Ho PM. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension. 2012;60:303-309.
10. Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chatellier G, Laurent S, Menard J, Plouin PF. Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study. J Hypertens. 2012;30:1656-1664.
11. Mancia G. Additional drug treatment in resistant hypertension: need for randomized studies. J Hypertens. 2012;30:1514-1515.
12. Hermida RC, Ayala DE, Mojón A, Fontao MJ, Fernández JR. Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int. 2011;28:601-610.
13. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596-606.
14. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension. 2011;57:880-886.
15. Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58:765-773.
16. Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med. 2012;367:2204-2213.
17. The ONTARGET Investigators.Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
18. Mancia G, Parati G, Bilo G, et al. Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). Hypertension. 2012;60:1400-1406.
19. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012;59:1110-1117.
20. Cushman WC, Bakris GL, White WB, Weber MA, Sica D, Roberts A, Lloyd E, Kupfer S. Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertension. Hypertension. 2012;60:310-318.
21. Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, Einhorn PT, Franklin SS, Papademetriou V, Ong ST, Eckfeldt JH, Furberg CD, Calhoun DA, Davis BR; Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Collaborative Research Group. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59:926-933.
22. Kostis WJ, Thijs L, Richart T, Kostis JB, Staessen JA. Persistence of mortality reduction after the end of randomized therapy in clinical trials of blood pressure-lowering medications. Hypertension. 2010;56:1060-1068.
23. van Onzenoort HA, Menger FE, Neef C, Verberk WJ, Kroon AA, de Leeuw PW, van der Kuy PH. Participation in a clinical trial enhances adherence and persistence to treatment: a retrospective cohort study. Hypertension. 2011;58:573-578.
24. Sever PS. The Anglo-Scandinavian Cardiac Outcomes Trial: implications and further outcomes. Hypertension. 2012;60:248-259.
25. Larstorp AC, Ariansen I, Gjesdal K, Olsen MH, Ibsen H, Devereux RB, Okin PM, Dahlöf B, Kjeldsen SE, Wachtell K. Association of pulse pressure with new-onset atrial fibrillation in patients with hypertension and left ventricular hypertrophy: the Losartan Intervention For Endpoint (LIFE) reduction in hypertension study. Hypertension. 2012;60:347-353.
26. Rossignol P, Cridlig J, Lehert P, Kessler M, Zannad F. Visit-to-visit blood pressure variability is a strong predictor of cardiovascular events in hemodialysis: insights from FOSIDIAL. Hypertension. 2012;60:339-346.
27. Matsui Y, O'Rourke MF, Hoshide S, Ishikawa J, Shimada K, Kario K. Combined Effect of Angiotensin II Receptor Blocker and Either a Calcium Channel Blocker or Diuretic on Day-by-Day Variability of Home Blood Pressure: The Japan Combined Treatment With Olmesartan and a Calcium-Channel Blocker Versus Olmesartan and Diuretics Randomized Efficacy Study. Hypertension. 2012;59:1132-1138.
28. Jennings GL, Sudhir K. Initial therapy of primary hypertension. Med J Aust. 1990;152:198-203.
29. Egan BM, Bandyopadhyay D, Shaftman SR, Wagner CS, Zhao Y, Yu-Isenberg KS. Initial monotherapy and combination therapy and hypertension control the first year. Hypertension. 2012;59:1124-1131.
30. Bavry AA, Pepine CJ. Treatment of hypertension: lower is better, or is it? Hypertension. 2012;60:281-282.
31. Mizuno R, Fujimoto S, Saito Y, Okamoto Y. Optimal antihypertensive level for improvement of coronary microvascular dysfunction: the lower, the better? Hypertension. 2012;60:326-332.
32. Roman MJ, Howard BV, Howard WJ, Mete M, Fleg JL, Lee ET, Devereux RB. Differential impacts of blood pressure and lipid lowering on regression of ventricular and arterial mass: the Stop Atherosclerosis in Native Diabetics Trial. Hypertension. 2011;58:367-371.
33. Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB. Implications of new hypertension guidelines in the United States. Hypertension. 2012;60:639-644.
34. Stewart S, Carrington MJ, Swemmer CH, et al.; VIPER-BP Study Investigators. Effect of intensive structured care on individual blood pressure targets in primary care: multicentre randomised controlled trial. BMJ. 2012;345:e7156.
35. Dickinson BD, Havas S; Council on Science and Public Health, American Medical Association. Reducing the population burden of cardiovascular disease by reducing sodium intake: a report of the Council on Science and Public Health. Arch Intern Med. 2007;167:1460-1468.
36. O'Donnell MJ, Yusuf S, Mente A, Gao P, Mann JF, Teo K, McQueen M, Sleight P, Sharma AM, Dans A, Probstfield J, Schmieder RE. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA. 2011;306:2229-2238.
37. Hummel SL, Seymour EM, Brook RD, Kolias TJ, Sheth SS, Rosenblum HR, Wells JM, Weder AB. Low-sodium dietary approaches to stop hypertension diet reduces blood pressure, arterial stiffness, and oxidative stress in hypertensive heart failure with preserved ejection fraction. Hypertension. 2012;60:1200-1206.
38. Soedamah-Muthu SS, Verberne LD, Ding EL, Engberink MF, Geleijnse JM. Dairy consumption and incidence of hypertension: a dose-response metaanalysis of prospective cohort studies. Hypertension. 2012;60:1131-1137.
39. West SG, Gebauer SK, Kay CD, Bagshaw DM, Savastano DM, Diefenbach C, Kris-Etherton PM. Diets containing pistachios reduce systolic blood pressure and peripheral vascular responses to stress in adults with dyslipidemia. Hypertension. 2012;60:58-63.
40. Zhang X, Qi Q, Liang J, Hu FB, Sacks FM, Qi L. Neuropeptide Y promoter polymorphism modifies effects of a weight-loss diet on 2-year changes of blood pressure: the preventing overweight using novel dietary strategies trial. Hypertension. 2012;60:1169-1175.
41. Meredith IT, Friberg P, Jennings GL, Dewar EM, Fazio VA, Lambert GW, Esler MD. Exercise training lowers resting renal but not cardiac sympathetic activity in humans. Hypertension. 1991;18:575-582.
42. Cornelissen VA, Fagard RH, Coeckelberghs E, Vanhees L. Impact of resistance training on blood pressure and other cardiovascular risk factors: a metaanalysis of randomized, controlled trials. Hypertension. 2011;58:950-958.